Vitamin D and Dementia Risk — A Research Summary

Vitamin D receptors are widely distributed throughout the brain, including in hippocampus and prefrontal cortex — regions critical for memory and executive function. Vitamin D influences neurotrophic factor expression (including BDNF and nerve growth factor), modulates neuroinflammation, regulates calcium homeostasis in neurons, and promotes amyloid-beta clearance. These are mechanisms directly relevant to Alzheimer's pathology.

Vitamin D also acts on the cerebrovascular system, regulating endothelial function and reducing the risk of small vessel disease — the substrate of vascular cognitive impairment.

Observational evidence is striking. A 2014 study in Neurology (1,658 participants, 6-year follow-up) found that people with severe vitamin D deficiency (below 25 nmol/L) had 122% greater risk of Alzheimer's and 51% greater risk of all-cause dementia compared to people with sufficient levels. A 2022 analysis of UK Biobank data (294,514 participants) found vitamin D supplementation associated with 40% lower dementia risk.

RCT evidence is less conclusive but moving in a positive direction. The VITAL trial (25,871 participants, 5 years, 2000 IU/day vitamin D3) showed no significant benefit for dementia specifically, but was designed primarily for cardiovascular and cancer outcomes. The COSMOS-Mind sub-study (2,262 older adults, 3 years, 2000 IU/day) found that vitamin D did not improve cognitive performance overall, but participants with lower baseline cognitive function showed benefit.

The gap between observational and RCT evidence may reflect supplementation occurring too late in the disease process, insufficient doses, or the fact that raising levels in people who are already sufficient has no additional benefit — the key effect may be preventing deficiency rather than optimizing already-adequate levels.

Promising. The observational association between deficiency and dementia risk is among the strongest in the cognitive health literature. The RCT evidence for supplementation in unselected older adults is weak, but there are strong reasons to believe that preventing or correcting deficiency is beneficial. Testing and correcting deficiency is more defensible than blanket supplementation of people with adequate levels.

Most positive observational associations are seen when blood levels (25-hydroxyvitamin D) are above 50 nmol/L (20 ng/mL). Optimal for cognitive health may be higher — 75-125 nmol/L (30-50 ng/mL). Supplementation doses needed to reach these levels vary enormously by baseline, sun exposure, age, and body weight. Most adults in northern latitudes require 1000-4000 IU/day of vitamin D3 to maintain sufficient levels.

Vitamin D toxicity is possible at very high doses (>10,000 IU/day sustained). At 1000-4000 IU/day, the risk is negligible for most adults. Taking vitamin D3 with vitamin K2 (specifically MK-7) is increasingly recommended to direct calcium appropriately — D3 increases calcium absorption, K2 directs it to bone rather than soft tissue. Testing blood levels is the most rational approach rather than using fixed doses without measurement.

Test your vitamin D level (25-OH vitamin D blood test). If deficient (below 50 nmol/L), correct it — this is one of the more defensible cognitive health interventions. Maintaining levels in the 75-125 nmol/L range during winter months, when sun exposure is minimal, is reasonable. For people already in the optimal range, additional supplementation has little RCT support.